SGMO - Sangamo Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
9.51
-1.29 (-11.94%)
At close: 4:00PM EST

9.51 0.00 (0.00%)
After hours: 6:51PM EST

Stock chart is not supported by your current browser
Previous Close10.80
Open10.16
Bid9.33 x 1000
Ask9.49 x 900
Day's Range9.00 - 10.49
52 Week Range9.00 - 27.50
Volume5,834,670
Avg. Volume2,243,613
Market Cap970.904M
Beta (3Y Monthly)3.46
PE Ratio (TTM)N/A
EPS (TTM)-0.68
Earnings DateNov 7, 2018 - Nov 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est26.14
Trade prices are not sourced from all markets
  • Here's Why Sangamo Therapeutics Lost 12% Today
    Motley Fool6 hours ago

    Here's Why Sangamo Therapeutics Lost 12% Today

    Wall Street is growing increasingly concerned about the progress the company's making with a gene therapy for hemophilia A.

  • Cutting-edge biotech Sangamo stock dives 13% after JPMorgan cites ‘growing skepticism’ in downgrade
    MarketWatch9 hours ago

    Cutting-edge biotech Sangamo stock dives 13% after JPMorgan cites ‘growing skepticism’ in downgrade

    Sangamo is developing innovative gene-editing programs for many devastating diseases, but a J.P. Morgan analyst called it a ‘show-me story from here.’

  • MarketWatch15 hours ago

    Sangamo stock drops after J.P. Morgan downgrade

    Sangamo Therapeutics Inc. shares dropped as much as 10% in Wednesday premarket trade before evening out to a 4.6% decline after the company was downgraded to "neutral" at J.P. Morgan, with analyst Eric Joseph citing "growing skepticism about the company's lead development programs and their potential for value creation over the foreseeable future." Joseph also cut the company's price target by nearly 70% to $11. (Company shares closed at $10.80 on Tuesday.) Sangamo is a buzzy biotechnology company that focuses on a type of cutting-edge gene editing that utilizes "zinc finger" proteins. But whether the company's SB-525 program for hemophilia A is working "continues to elude, now with indefinite timelines," Joseph said, questioning whether the company can beat further-along competitors like BioMarin Pharmaceutical Inc. and Spark Therapeutics Inc. . The analyst also had questions about the company's SB-913 program, being developed for a metabolic disorder called Hunter syndrome; early results from a trial were recently released to skepticism, causing Sangamo shares to plummet. "We do believe that the breadth of the pipeline offers several potential catalysts longer term (12-18 months), but with management credibility increasingly coming into play, net-net, we view SGMO as a show-me story from here," Joseph said. Sangamo shares have dropped 32.1% over the last three months, compared with a 3.5% decline in the S&P 500 .

  • A Financial Overview of CRISPR Therapeutics in November
    Market Realist2 days ago

    A Financial Overview of CRISPR Therapeutics in November

    CRISPR Therapeutics (CRSP) reported revenues of $563,000 in the third quarter—compared to $2.4 million in the third quarter of 2017. CRISPR Therapeutics reported net revenues of $3.0 million over the first nine months of 2018—compared to $8.7 million during the same period in 2017. CRISPR Therapeutics’ net revenues are mainly from collaborations undertaken by the company.

  • CRISPR Therapeutics: Analysts’ View in November
    Market Realist3 days ago

    CRISPR Therapeutics: Analysts’ View in November

    On November 9, CRISPR Therapeutics’ (CRSP) stock price closed at $36.37, which is an ~3.53% decline from its close of $37.70 on November 8. On November 7, after the company reported its third-quarter financial results, the stock price grew ~10.81% to $38.85 from the close of $35.06 on November 6.

  • Here's Why Sangamo Therapeutics Inc. Fell 25.3% in October
    Motley Fool5 days ago

    Here's Why Sangamo Therapeutics Inc. Fell 25.3% in October

    Following the acquisition of a start-up biotech, Sangamo saw its stock tumble along with the rest of its industry.

  • Thomson Reuters StreetEvents6 days ago

    Edited Transcript of SGMO earnings conference call or presentation 8-Nov-18 10:00pm GMT

    Q3 2018 Sangamo Therapeutics Inc Earnings Call

  • Sangamo Therapeutics (SGMO) Reports Q3 Loss, Lags Revenue Estimates
    Zacks6 days ago

    Sangamo Therapeutics (SGMO) Reports Q3 Loss, Lags Revenue Estimates

    Sangamo (SGMO) delivered earnings and revenue surprises of 0.00% and -41.53%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • PR Newswire6 days ago

    Sangamo Therapeutics Reports Third Quarter 2018 Financial Results

    RICHMOND, Calif., Nov. 8, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (SGMO) today reported third quarter 2018 financial results and recent business highlights. "I'm pleased with our continued execution toward our vision to transform Sangamo into the premier genomic medicines company," said Sandy Macrae, CEO of Sangamo. In September, Sangamo presented 16-week clinical results from the first two cohorts of the Phase 1/2 CHAMPIONS Study evaluating SB-913 for Mucopolysaccharidosis Type II (MPS II), including dose-dependent reductions in glycosaminoglycans (GAGs) in the second cohort (1e13 vector genomes per kilogram of body weight, or vg/kg).

  • PR Newswire8 days ago

    Sangamo Therapeutics Announces Participation At Upcoming Investor Conferences

    RICHMOND, Calif. , Nov. 6, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today that management will participate in the following healthcare investor conferences in November. ...

  • PR Newswire14 days ago

    Sangamo Therapeutics Announces Third Quarter 2018 Conference Call and Webcast

    RICHMOND, Calif. , Nov. 1, 2018 /PRNewswire/ --   Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today that the Company will release its third quarter 2018 financial results after the market closes ...

  • What's in Store for Sangamo (SGMO) This Earnings Season?
    Zacks17 days ago

    What's in Store for Sangamo (SGMO) This Earnings Season?

    On Sangamo's (SGMO) Q3 2018 conference call, investor focus will be on the company's progress with its genome editing and gene regulation technology platform.

  • Is Sangamo Therapeutics Inc. a Buy?
    Motley Fool28 days ago

    Is Sangamo Therapeutics Inc. a Buy?

    Can this beaten-down gene-editing and gene therapy biotech bounce back?

  • GlobeNewswire29 days ago

    Analysis: Positioning to Benefit within New York, KB Home, Sangamo Therapeutics, INTL FCStone, Maiden, and MobileIron — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Oct. 17, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Taking Stock of Gilead’s Operational Performance
    Market Realistlast month

    Taking Stock of Gilead’s Operational Performance

    Gilead Sciences’ (GILD) selling, general, and administrative expenses increased from $897.0 million in the second quarter of 2017 to $980.0 million in the second quarter. The increase was due to higher stock-based compensation expenses and costs after the Kite acquisition.

  • Sangamo Therapeutics Stock Is in Bearish Territory
    Market Realistlast month

    Sangamo Therapeutics Stock Is in Bearish Territory

    On October 4, Sangamo Therapeutics (SGMO) stock ended the trading day at $14.81—down ~3.4% from the previous day’s close. The stock registered its 52-week high of $27.50 on February 22. Sangamo Therapeutics reported its 52-week low of $11.30 on October 26, 2017. Currently, the stock is trading ~5.5% lower than its 50-day moving average of $15.68 and ~9% lower than its 200-day moving average of $16.27.

  • Sangamo Therapeutics: Analysts Expect 88% Upside Potential
    Market Realistlast month

    Sangamo Therapeutics: Analysts Expect 88% Upside Potential

    Sangamo Therapeutics (SGMO), a clinical stage biotechnology firm, is focused on developing gene-based therapies using industry-leading technology platforms in gene therapy, cell therapy, genome editing, and gene regulation. The company has collaborations with a number of leading pharmaceuticals firms including Gilead Sciences (GILD), Sanofi (SNY), and Pfizer (PFE) to develop a wide range of genomic therapies. In this part, we’ll discuss Sangamo Therapeutics’ recent recommendations and target prices from Wall Street analysts.

  • PR Newswirelast month

    Sangamo and TxCell announce the completion of the acquisition by Sangamo of majority of TxCell ordinary shares

    RICHMOND, Calif. and VALBONNE, France, Oct. 1, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (SGMO) and TxCell S.A. (TXCL.PA) today jointly announced the completion by Sangamo of the acquisition of ordinary shares of TxCell, at a price of €2.58 per share in cash, representing approximately 53% of the share capital and voting rights of TxCell, as per the terms of the Share Purchase Agreement entered into on July 20, 2018 (the "SPA") and announced previously by TxCell and Sangamo in a joint press release dated July 23, 2018.

  • Implied Volatility Surging for Sangamo Therapeutics (SGMO) Stock Options
    Zacks2 months ago

    Implied Volatility Surging for Sangamo Therapeutics (SGMO) Stock Options

    Investors need to pay close attention to Sangamo Therapeutics (SGMO) stock based on the movements in the options market lately.

  • PR Newswire2 months ago

    Sangamo Therapeutics Announces Participation At Upcoming Investor and Industry Conferences

    RICHMOND, Calif. , Sept. 24, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today that management will participate in the following healthcare investor and industry conferences ...

  • ACCESSWIRE2 months ago

    Major Stem Cell Breakthroughs Giving Investors Big Opportunity

    HENDERSON, NV / ACCESSWIRE / September 14, 2018 / Last week, Sangamo Therapeutics became the first company to edit a patient's DNA inside the body, usually the process is done outside the body. This is ...

  • Why Analysts Remain Bullish on Sangamo Therapeutics
    Market Realist2 months ago

    Why Analysts Remain Bullish on Sangamo Therapeutics

    Its net loss per share was $0.17 in the second quarter of 2017. Six of them have given Sangamo stock a “buy” or higher rating, and one has rated it a “hold.” The mean rating for Sangamo stock is 1.71 with a target price of $27.83, implying an upside potential of 89.32% over its closing price of $14.70 on September 11. In comparison, peers Biogen (BIIB), BioMarin Pharmaceutical (BMRN), and Gilead Sciences (GILD) have mean ratings of 2, 1.78, and 2.15, respectively, and target prices of $389.20, $119.35, and $87.87, respectively.

  • Sangamo Therapeutics: The Promise of Zinc Fingers
    Market Realist2 months ago

    Sangamo Therapeutics: The Promise of Zinc Fingers

    Sangamo Therapeutics (SGMO) is focused on developing and commercializing novel genomic therapies. Its genome editing and gene regulation platform is based on the engineering of a type of transcription factors called zinc finger DNA binding proteins (or ZFP) that naturally occur in humans. Sangamo has entered into key collaborations with Kite Pharma, a subsidiary of Gilead Sciences (GILD) and Pfizer (PFE).

  • Audentes Therapeutics’ Promising Product Pipeline
    Market Realist2 months ago

    Audentes Therapeutics’ Promising Product Pipeline

    Gene therapy involves repairing or replacing disease-causing genes. Investor interest in gene therapy stocks has remained buoyant throughout 2018. According to Allied Market Research, the gene therapy market is expected to grow at a 33.3% CAGR (compound annual growth rate) to $4.4 billion by 2023.

  • Who Are The Major Shareholders Of Sangamo Therapeutics Inc (NASDAQ:SGMO)?
    Simply Wall St.2 months ago

    Who Are The Major Shareholders Of Sangamo Therapeutics Inc (NASDAQ:SGMO)?

    A look at the shareholders of Sangamo Therapeutics Inc (NASDAQ:SGMO) can tell us which group is most powerful. Insiders often own a large chunk of younger, smaller, companies while hugeRead More...